You just read:

Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma

News provided by

Nektar Therapeutics; Bristol-Myers Squibb

Aug 01, 2019, 07:00 ET